Metastatic castration-resistant prostate cancer (CRPC): Preclinical and clinical evidence for the sequential use of novel therapeutics

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 555-566

  Mukherji, Deborah ^a   Omlin, Aurelius ^b,c   Pezaro, Carmel ^b,c   Shamseddine, Ali ^a   De Bono, Johann ^b,c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone acetate; Androgen receptor signaling; Cabazitaxel; Castration resistant prostate cancer (CRPC); Enzalutamide; Sequential treatment strategies

Indexed keywords

ANIMAL; DRUG DEVELOPMENT; HUMAN; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DRUG DISCOVERY; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

EID: 84905089818     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9473-1     Document Type: Review

References (74)

1. Jemal, A., et al. (2010). Cancer statistics, 2010. CA: a Cancer Journal for Clinicians, 60(5), 277-300.
2. LaVecchia, C., et al. (2010). Cancermortality in Europe, 2000-2004, and an overview of trends since 1975. Annals of Oncology, 21(6), 1323-1360.
3. Kantoff, P. W., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine, 363(5), 411-422.
4. Ryan, C. J., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine, 368(2), 138-148.
5. de Bono, J. S., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. The New England Journal of Medicine, 364(21), 1995-2005.
6. de Bono, J. S., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet, 376(9747), 1147-1154.
7. Scher, H. I., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine, 367(13), 1256-1257.
8. Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fossa, S. D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine, 369(3), 213-23.
9. Tannock, I. F., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351(15), 1502-1512. (Pubitemid 39315317)
10. Ryan, C., Smith, M., de Bono, J., Molina, A., Logothetis, C., de Souza, P., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine, 368(2), 138-48.
11. Omlin, A., et al. (2013). Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. European Urology, 64(2), 300-306.
12. Nilsson, S., et al. (2013). Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Journal of Clinical Oncology, 31(suppl 6; abstr 19), 2013.
13. Logothetis, C. J., et al. (2012). Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomized trial. Lancet Oncology, 13(12), 1210-1217.
14. Sternberg, C. N., et al. (2013). Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Annals of Oncology, 24(4), 1017-1025.
15. Liede A, GO., Bennett B, Wong S, Prevalence of non-metastatic castration resistant prostate cancer in Europe. Ann Oncol, 2012. 29(Suppl 9 abstract 902P).
16. Lecouvet, F. E., et al. (2012). Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99 m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? European Urology, 62(1), 68-75.
17. Smith, M. R., et al. (2005). Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Journal of Clinical Oncology, 23(13), 2918-2925. (Pubitemid 46224110)
18. Smith, M. R., et al. (2012). Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. Lancet, 379(9810), 39-46.
19. NCCN. NCCN Clinical Practice Guidelines Prostate Cancer Version 2 2013. 2013 21/02/2013]; Available from: http://www.nccn.org/professionals/physician- gls/pdf/prostate.pdf.
20. Berthold, D. R., et al. (2008). Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clinical Cancer Research, 14(9), 2763-2767.
21. Huber, M. L., et al. (2012). Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. Journal of the National Cancer Institute, 104(4), 273-279.
22. Saad, F., et al. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94(19), 1458-1468.
23. Fizazi, K., et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet, 377(9768), 813-822.
24. Scher, H. I., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine, 367(13), 1187-1197.
25. Mukherji, D., Eichholz, A., & De Bono, J. S. (2012). Management of metastatic castration-resistant prostate cancer: recent advances. Drugs, 72(8), 1011-1028.
26. Ferraldeschi, R., et al. (2013). Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. Annual Review of Medicine, 64, 1-13.
27. Attard, G., Cooper, C. S., & de Bono, J. S. (2009). Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell, 16(6), 458-462.
28. Nelson, P. S. (2012). Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. Journal of Clinical Oncology, 30(6), 644-646.
29. Grasso, C. S., et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature, 487(7406), 239-243.
30. Barbieri, C. E., et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1, and MED12 mutations in prostate cancer. Nature Genetics, 44(6), 685-689.
31. Richards, J., et al. (2012). Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Research, 72(9), 2176-2182.
32. Albiges, L., et al. (2013). Is there a withdrawal syndrome with abiraterone acetate (AA)? Journal of Clinical Oncology, 31(suppl 6; abstr 89), 2013.
33. Montgomery, R. B., et al. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research, 68(11), 4447-4454.
34. Titus, M. A., et al. (2005). Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research, 11(13), 4653-4657. (Pubitemid 41557182)
35. Locke, J. A., et al. (2008). Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research, 68(15), 6407-6415.
36. Cai, C., et al. (2011). Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Research, 71(20), 6503-6513.
37. Li, R., et al. (2012). Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clinical Cancer Research, 18(13), 3571-3579.
38. Efstathiou, E., et al. (2012). Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. Journal of Clinical Oncology, 30(6), 637-643.
39. Mostaghel, E. A., et al. (2011). Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical Cancer Research, 17(18), 5913-5925.
40. Efstathiou, E., et al. (2011). MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report. Journal of Clinical Oncology, 29(suppl; abstr 4501), 2011.
41. Scher, H. I., et al. (2010). Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 375(9724), 1437-1446.
42. Tran, C., et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324(5928), 787-790.
43. Li, Y., et al. (2013). Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Research, 73(2), 483-489.
44. Darshan, M. S., et al. (2011). Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Research, 71(18), 6019-6029.
45. Seruga, B., Ocana, A., & Tannock, I. F. (2011). Drug resistance in metastatic castration-resistant prostate cancer. Nature Reviews. Clinical Oncology, 8(1), 12-23.
46. Yap, T. A., Pezaro, C. J., & de Bono, J. S. (2012). Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 12(9), 1129-1136.
47. Vrignaud, P., et al. (2013). Preclinical antitumor activity of cabazitaxel, a semi-synthetic taxane active in taxane-resistant tumors. Clinical Cancer Research, 19(11), 2973-83.
48. Nelson, J. B., et al. (2008). Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer, 113(9), 2478-2487.
49. Smith, M.R., et al., (2012). ARN-509 in Men with High Risk Non-Metastatic Castration-Resistant Prostate Cancer. Annals of Oncology 23(suppl 9; abstr 3109).
50. Guyatt, G. H., et al. (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336(7650), 924-926. (Pubitemid 351632017)
51. Mezynski, J., et al. (2012). Antitumor activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Annals of Oncology, 23(11), 2943-2947.
52. Aggarwal, R. R., et al. (2012). Response to ketoconazole (keto) or docetaxel (D) following clinical progression on abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology, 30(suppl; abstr 4664), 2012.
53. Chi, K. N., et al. (2012). Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 30(suppl 5; abstr 15), 2012.
54. Mukherji, D., et al. (2012) Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel. Journal of Clinical Oncology 30 (suppl 5; abstr 17), 2012.
55. Mita, A. C., et al. (2009). Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h. infusion every 3 weeks in patients with advanced solid tumors. Clinical Cancer Research, 15(2), 723-730.
56. Hunter, J., et al. (1993). Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. Journal Biology Chemical, 268(20), 14991-14997. (Pubitemid 23206648)
57. Wissing, M.D., et al. (2013). A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrateresistant prostate cancer patients. European Journal of Cancer, 49(suppl 2; abstr 2904).
58. Sonpavde, G., et al. (2013). Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC). European Journal of Cancer, 49(suppl 2; abstr 2905).
59. Loriot, Y., et al. (2013). Antitumor activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology, 24(7), 1807-12.
60. Noonan, K.L., et al. (2013). Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Annals of Oncology, 24(7), 1802-7.
61. Rathkopf, D. E., et al. (2013). ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 31(suppl 6; abstr 48), 2013.
62. Bianchini, D., et al. (2014). Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. European Journal of Cancer, 50(1), 78-94).
63. Schrader, AJ. et al. (2014). Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. European Urology, 65(1), 30-6.
64. Zhu, M. L., et al. (2010). Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Research, 70(20), 7992-8002.
65. Pezaro, C. J., et al. (2013). Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. Journal of Clinical Oncology, 31(suppl 6; abstr 155), 2013.
66. Sella, A., et al. (2013). Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer. Journal of Clinical Oncology, 31(suppl 6; abstr 186), 2013.
67. Galsky, M. D., & Vogelzang, N. J. (2010). Docetaxel-based combination therapy for castration-resistant prostate cancer. Annals of Oncology, 21(11), 2135-2144.
68. Kelly, W. K., et al. (2012). Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of Clinical Oncology, 30(13), 1534-1540.
69. Petrylak, D.P., et al., A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (dp) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): The MAINSAIL Trial. ESMO conference 2012 LBA24, 2012.
70. Tannock, I., et al. (2013). Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): results from the multinational phase III trial (VENICE). Journal of Clinical Oncology, 31(suppl 6; abstr 13), 2013.
71. Quinn, D. I., et al. (2012). SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) formen with advanced castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology, 30(suppl; abstr 4511), 2012.
72. Araujo, J. C., et al. (2013). Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. Journal of Clinical Oncology, 31(suppl 6; abstr LBA8), 2013.
73. Morris, M. J., et al. (2012). A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases. Journal of Clinical Oncology, 30(suppl; abstr TPS4694), 2012.
74. Small, E. J., et al. (2013). A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 31(suppl 6; abstr 114), 2013.